Oncternal Therapeutics - Company Profile
Powered by
All the data and insights you need on Oncternal Therapeutics in one report.
$295
- Save hours of research time and resources with
our up-to-date Oncternal Therapeutics Strategy Report
- Understand Oncternal Therapeutics position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Oncternal Therapeutics’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
---|---|---|---|---|
08 Mar 2024 | Oncternal Therapeutics to Raise USD250 Million in Equity Offerings | Equity Offering | - |
Oncternal Therapeutics |
24 Jan 2024 | Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease | Grant |
National Institute of Neurological Disorders and Stroke
|
Oncternal Therapeutics |
15 Mar 2023 | Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease | Grant |
National Institute of Neurological Disorders and Stroke
|
Oncternal Therapeutics |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer